Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.

ABSTRACT:

Background

Previous research indicates that a combination vaccine targeting different stages of the malaria life cycle is likely to provide the most effective malaria vaccine. This trial was the first to combine two existing vaccination strategies to produce a vaccine that induces immune responses to both the pre-erythrocytic and blood stages of the P. falciparum life cycle.

Methods

This was a Phase I/IIa study of a new combination malaria vaccine FFM ME-TRAP+PEV3A. PEV3A includes peptides from both the pre-erythrocytic circumsporozoite protein and the blood-stage antigen AMA-1. This study was conducted at the Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK. The participants were healthy, malaria naïve volunteers, from Oxford. The inte

SUBMITTER: Thompson FM 

PROVIDER: S-EPMC2204057 | biostudies-literature | 2008 Jan

REPOSITORIES: biostudies-literature